R. Gaggero
Istituto Giannina Gaslini
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by R. Gaggero.
Neurology | 2002
Maura Faraci; Edoardo Lanino; Giorgio Dini; M. P. Fondelli; Giuseppe Morreale; Sandro Dallorso; Carla Manzitti; Maria Grazia Calevo; R. Gaggero; Elio Castagnola; Riccardo Haupt
Objective: To describe and evaluate the incidence and risk factors of severe neurologic events (SNE) in pediatric recipients of allogeneic or autologous hematopoietic stem cell transplantation (HSCT) for hematologic or nonhematologic diseases. Methods: Retrospective analysis of 272 consecutive children admitted to the G. Gaslini Children’s Research Institute and given HSCT (70 from unrelated donors, 115 from related donors, and 87 autologous) between June 1985 and January 2001. Results: Thirty-seven children (13.6%) developed SNE after a median of 90 days (range, 5 days to 8.8 years) after HSCT. Cyclosporine A (CSA) neurotoxicity was the most frequent SNE (n = 21), followed by irradiation or chemotherapy injury (n = 7), CNS infections (n = 7), cerebrovascular events (n = 3), and immune-mediated etiology SNE (n = 2). Eleven patients (30%) died because of the neurologic complications. Type of HSCT, treatment with total body irradiation (TBI), acute graft-vs-host disease (GvHD), GvHD >grade 2, and treatment with CSA were associated with a significant increased risk of SNE. Conclusions: Severe neurologic complications are frequent (14%) among children receiving HSCT, causing 8.5% of deaths after transplant. Transplant from allogeneic donor, especially if unrelated, the development of severe acute GvHD grade >2, and the use of TBI in the preparative regimen are the main risk factors for such complications.
Neurology | 2006
Francesca Madia; Pasquale Striano; Elena Gennaro; M. Malacarne; R. Paravidino; Roberta Biancheri; M. Budetta; Maria Roberta Cilio; R. Gaggero; M. Pierluigi; Carlo Minetti; Federico Zara
Objective: To identify cryptic chromosomal deletions involving SCN1A in patients with severe myoclonic epilepsy of infancy (SMEI). Methods: Thirty-nine patients with SMEI and without SCN1A point mutations and their parents were typed with 14 intragenic SCN1A polymorphisms to identify hemizygosity. The parental origin and the extent of genomic deletions were determined by fluorescence in situ hybridization analysis using genomic clones encompassing chromosome 2q24.3-q31.1. Deletion breakpoints were more finely mapped by typing single-nucleotide polymorphisms and microsatellite markers. Results: We identified three patients with SMEI who had genomic deletions encompassing the SCN1A locus. Deletion size was between 607 kb and 4.7 Mb. Deletions originated de novo from paternal chromosome in all subjects. One patient had central precocious puberty and palatoschisis. Genotype–phenotype correlations suggest that these clinical features are due to genes centromeric to SCN1A. Conclusions: Patients with severe myoclonic epilepsy of infancy (SMEI) lacking SCN1A point mutations should be investigated for cryptic chromosomal deletions involving SCN1A. Clinical features other than epilepsy could be associated with SMEI as a consequence of deletions in contiguous genes.
Bone Marrow Transplantation | 2003
Maura Faraci; Edoardo Lanino; Sandro Dallorso; Giuseppe Morreale; B. Cappelli; R. Gaggero; Giorgio Dini; Riccardo Haupt; M. P. Fondelli
Summary:Mesial temporal sclerosis (MTS) is a common finding in patients with intractable temporal lobe epilepsy (TLE). In this report, we retrospectively reviewed the neuroimaging results of four children who underwent allogeneic hematopoietic stem cell transplantation (allo-HSCT), and who developed recurrent, partial, intractable seizures following a first event caused by cyclosporine-A (CSA) neurotoxicity. Neuroradiologic findings of MTS were demonstrated in all these patients. We suggest that MTS may be a consequence of CSA neurotoxicity, which induces repeated seizures, associated with other predisposing conditions, as well as being a consequence of the underlying disease and its treatment, and of severe graft-versus-host disease (GvHD).
Journal of Child Neurology | 2006
R. Gaggero; Riccardo Haupt; Maria Paola Fondelli; Raffaella De Vescovi; Alessia Marino; Edoardo Lanino; Sandro Dallorso; Maura Faraci
The long-term evolution to intractable epilepsy in children treated with cyclosporine administered for graft-versus-host-disease after hematopoietic stem cell transplantation was evaluated. In a group of 185 children treated with cyclosporine after bone marrow transplantation, 15 (8%) presented with acute seizures that were generalized in 7 and focal in 7 and had absence status in 1. Electroencephalography (EEG) and neuroimaging showed predominant abnormalities in the occipital regions. One patient died shortly after the seizure; in seven cases, seizures remitted, whereas relapses were observed in seven others. After the first year, seizures persisted chronically in four cases and evolved to intractable epilepsy. Focal temporal epilepsy was diagnosed in three cases, whereas in the fourth case, a multifocal epilepsy was observed. Magnetic resonance imaging (MRI) detected mesial temporal sclerosis in all of these cases. The risk factors associated with evolution to epilepsy included lower age at transplantation (3—5 years), more than one relapsing seizure in the first year after transplantation, and longer treatment with cyclosporine. Not only can cyclosporine cause acute central nervous system toxicity, it can also determine intractable epilepsy associated with mesial temporal sclerosis. (J Child Neurol 2006;21:861—866; DOI 10.2310/7010.2006.00196).
Journal of Child Neurology | 2001
R. Gaggero; Raffaella Devescovi; Lino Nobili; M. G. Baglietto; Marco Zucconi; Alessia Schinardi
We report the case of a 13-year-old boy who complained of complex motor episodes during sleep characterized by sudden arousal followed by deambulation associated with automatic movements and vocalization. His family history included both epileptic and psychiatric disorders. The patient himself presented psychopathologic traits and adaptive difficulties. In support of an epileptic origin of these phenomena were the stereotyped fashion in which they appeared and their responsiveness to carbamazepine. We classified the present case as a nocturnal frontal epilepsy with variable manifestations that can be classified as paroxysmal arousals, paroxysmal dystonia, and epileptic nocturnal wanderings. It was possible to differentiate such events from the most common parasomnias on the basis of videopolysomnographic studies. (J Child Neurol 2001;16:628-631).
Neuropediatrics | 2005
Maria Margherita Mancardi; Francesca Fazzini; Andrea Rossi; R. Gaggero
Bollettino - Lega Italiana contro l'Epilessia | 2008
S. Ricci; M. S. Vari; Maria Margherita Mancardi; M. P. Baglietto; R. Gaggero
Bollettino - Lega Italiana contro l'Epilessia | 2008
M. S. Vari; Maria Margherita Mancardi; M. G. Baglietto; R. Gaggero; Giulia Prato; Edvige Veneselli; M. G. Marazzi
Bollettino - Lega Italiana contro l'Epilessia | 2008
Pasquale Striano; F. Madia; Antonietta Coppola; Maria Margherita Mancardi; E. Gennaro; M. Budetta; Maria Roberta Cilio; C. Ciampa; Luca Errichiello; R. Gaggero; Federico Zara
Bollettino - Lega Italiana contro l'Epilessia | 2006
Maria Margherita Mancardi; Ubaldo Caruso; M. G. Baglietto; M. C. Schiaffino; E. Bonioli; Andrea Rossi; R. Gaggero